Nectero Medical is a clinical-stage biotech company pioneering novel therapies with a potential to treat aneurysmal disease and improve patients’ lives. The Company is led by a highly accomplished, multidisciplinary management team with input from an experienced board of directors and renowned physician leaders in vascular surgery and intervention. Nectero Medical is developing an investigational, locally-delivered endovascular treatment, Nectero Endovascular Aneurysm Stabilization Treatment (Nectero EAST®) System, with the potential to stabilize growth and minimize risk of rupture of small to mid-sized infrarenal abdominal aortic aneurysms (AAA).